Dichloromethane → (E)-N-(Tetrahydro-pyran-2-yloxy)-3-(1-{4-[1-(2-morpholin-4-yl-ethyl)-1H-[1,2,3]triazol-4-yl]-benzenesulfonyl}-1H-pyrrol-3-yl)-acrylamide

HRID 1445500ノート

反応式

HRID 1445500 の反応式
[O:1]1[CH2:6][CH2:5][N:4]([CH2:7][CH2:8][N:9]=[N+:10]=[N-:11])[CH2:3][CH2:2]1.O=C1O[C@H]([C@H](CO)O)C([O-])=C1O.[Na+].[C:25]([C:27]1[CH:32]=[CH:31][C:30]([S:33]([N:36]2[CH:40]=[CH:39][C:38](/[CH:41]=[CH:42]/[C:43]([NH:45][O:46][CH:47]3[CH2:52][CH2:51][CH2:50][CH2:49][O:48]3)=[O:44])=[CH:37]2)(=[O:35])=[O:34])=[CH:29][CH:28]=1)#[CH:26].C(Cl)Cl>O.CC(O)(C)C>[O:48]1[CH2:49][CH2:50][CH2:51][CH2:52][CH:47]1[O:46][NH:45][C:43](=[O:44])/[CH:42]=[CH:41]/[C:38]1[CH:39]=[CH:40][N:36]([S:33]([C:30]2[CH:29]=[CH:28][C:27]([C:25]3[N:11]=[N:10][N:9]([CH2:8][CH2:7][N:4]4[CH2:5][CH2:6][O:1][CH2:2][CH2:3]4)[CH:26]=3)=[CH:32][CH:31]=2)(=[O:35])=[O:34])[CH:37]=1

参加物

7

反応物 4

HCID 6344DichloromethaneHCID 27370154-(2-Azidoethyl)morpholineHCID 23667548Sodium AscorbateHCID 86621705(E)-3-[1-(4-Ethynyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-(tetrahydro-pyran-2-yloxy)-acrylamide

生成物 1

HCID 86621706(E)-N-(Tetrahydro-pyran-2-yloxy)-3-(1-{4-[1-(2-morpholin-4-yl-ethyl)-1H-[1,2,3]triazol-4-yl]-benzenesulfonyl}-1H-pyrrol-3-yl)-acrylamide収率 27%

試薬・触媒・溶媒 2

HCID 962Water溶媒HCID 6386tert-Butanol溶媒

実験手順

To a stirred mixture of 2-morpholino-ethylazide (0.30 mmol) in water (2 ml) are added CuSO4 pentahydrate (0.02 mmol), sodiumascorbate (0.04 mmol) and (E)-3-[1-(4-Ethynyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-(tetrahydro-pyran-2-yloxy)-acrylamide (0.30 mmol) in t-BuOH (1 ml) at room temperature. The reaction mixture is stirred over night. After addition of DCM the organic phase is separated, evaporated under reduced pressure and purified by prep. HPLC yielding 0.081 mmol of the title compound.

後処理

  1. customis separated
  2. customevaporated under reduced pressure
  3. custompurified by prep

出典と根拠

ORDレコード
ord-7276ac41b4d2443b9fead79ebdee4784
出典データセット
uspto-grants-2010_02
特許番号
US07666868B2

反応ノート

読み込み中…